Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross SC Actinic Keratosis Coverage | OpenPay…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South CarolinaPolicy N/A

    ACTINIC KERATOSIS - SCORE

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - South Carolina policy alerts

    Know when Blue Cross Blue Shield - South Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs step-therapy coverage for diclofenac sodium gel 3% used for actinic keratosis under the South Carolina Bronze 6T formulary. Coverage requires a trial of topical fluorouracil or topical imiquimod.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyACTINIC KERATOSIS - SCORE
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateSep 1, 2026
    Next Review DateN/A
    Key ActionDocument a trial of topical fluorouracil or topical imiquimod before requesting coverage of diclofenac sodium gel 3%.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Products affected
    3Required step therapies
    2Acceptable prerequisite therapies
    1Covered indication

    Coverage Criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Actinic Keratosis Initial Therapy

    Coverage requires the following step-therapy criterion.

    Required prior therapy: Trial of either topical fluorouracil or topical imiquimod

    Rytary

    Rytary SCORE criterion.

    Rytary step requirement: Trial of one generic carbidopa/levodopa-containing formulation

    Zonisade

    Zonisade SCORE criterion.

    Zonisade step requirement: Trial of generic zonisamide capsule

    Step applies to new starts only; continuation of prior therapy is approved.

    Required Provider Actions

    Step Therapy

    Topical Prerequisite Required

    Before requesting coverage for diclofenac sodium gel 3%, document a trial of either topical fluorouracil or topical imiquimod.

    • Required step: Trial of topical fluorouracil or topical imiquimod.
    Step Therapy

    Generic Carbidopa/Levodopa Trial Required

    Before requesting Rytary, document a trial of one generic carbidopa/levodopa-containing formulation.

    • Required step: Trial of one generic carbidopa/levodopa-containing formulation.
    Step Therapy

    Generic Zonisamide Trial Required

    For new starts, document a trial of generic zonisamide capsules before requesting Zonisade. Approve continuation when the patient is already receiving prior therapy.

    • New starts: Trial of generic zonisamide capsule required.
    • Continuation: Approve for continuation of prior therapy.

    Policy Background

    This policy addresses actinic keratosis and formulary sequencing for diclofenac sodium gel 3% under the South Carolina Bronze 6T formulary. Coverage requires a trial of either topical fluorouracil or topical imiquimod before diclofenac sodium gel 3% is covered.

    Initial Therapy Criteria

    Diclofenac Sodium Gel 3% Step Therapy

    Initial coverage requires the following prior topical therapy.

    Prior topical therapy trial

    • ONE of

      • Trial of topical fluorouracil
      • Trial of topical imiquimod

    Rytary Initial Therapy

    Initial coverage requires the following step-therapy criterion.

    Generic carbidopa/levodopa trial

    • Trial of one generic carbidopa/levodopa-containing formulation is required.

    Zonisade Initial Therapy

    Initial coverage requires the following step-therapy criterion.

    Generic zonisamide trial

    • Trial of generic zonisamide capsule is required.

      Step applies to new starts only.

    Continuation Therapy Criteria

    Zonisade Continuation

    Continuation of prior therapy is approved.

    Continuation of prior therapy: Approve for continuation of prior therapy.

    The step requirement applies to new starts only.

    Step-Therapy Requirements

    StepRequired therapy
    1Trial of either topical fluorouracil or topical imiquimod
    StepRequired therapy
    1Trial of one generic carbidopa/levodopa-containing formulation
    StepRequired therapy
    1Trial of generic zonisamide capsule. Step applies to new starts only. Approve for continuation of prior therapy.
    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyACTINIC KERATOSIS - SCORE
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateSep 1, 2026
    Next Review DateN/A
    Key ActionDocument a trial of topical fluorouracil or topical imiquimod before requesting coverage of diclofenac sodium gel 3%.
    SourceLink
    On This Page
    Coverage CriteriaRequired Provider ActionsPolicy BackgroundInitial Therapy CriteriaContinuation Therapy CriteriaStep-Therapy Requirements